Case Studies

Stamford, Connecticut


What if healthcare outcomes could be improved through artificial intelligence? Sema4, a patient-centered health intelligence company headquartered in Stamford, makes it possible. The rapidly growing startup is using Centrellis™, its unique advanced analytics platform, to build predictive models of human health to deliver personalized insights for healthcare providers and their patients in the areas of reproductive health and precision oncology, as well as more generalized genomic health screening and modeling across the spectrum of disease.

Sema4’s predictive modeling and natural language processing of medical records are also leveraged to deliver insights that can power informed decision-making across the drug discovery pipeline, from the best points of therapeutic intervention to clinical trial matching. Additionally, as part of its mission of advancing healthcare through data-driven insights, Sema4 processes thousands of industry-leading, information-based genomic tests a day and delivers breakthrough scientific research in collaboration with its health system and research clients and partners.

the support and resources

Connecticut Innovations has joined other premier investors in providing Sema4 with a blend of equity investment and loans. Connecticut Innovations was an investor in Sema4’s first round of external funding (Series B) in August 2019 and participated in its $121 million Series C financing in July 2020.

“Connecticut Innovations has been a tremendous partner to Sema4 since we first established a presence in Connecticut in 2017. We appreciate all the support, direction, and resources that Connecticut Innovations, along with many other core government and industry groups, has given us over the last few years as we have rapidly expanded our footprint in the state.”
Eric Schadt, Ph.D.
Founder and CEO, Sema4
the outcome

Today, Sema4 is a generator, aggregator, and analyzer of high-dimensional longitudinal patient health data, transforming this data into comprehensive solutions that advance diagnosis, treatment, and drug development. For example, Sema4 has predictive models for multiple cancers, integrating clinical information with genomic profiling to provide health systems with the most comprehensive view of a cancer patient, their tumor, and how best to diagnose or treat them.

In 2020, the company opened a state-of-the-art clinical laboratory in Stamford—its second in Connecticut—that will enable it to process more tests, expand its digital health services, and deliver additional scientific research. The new 70,000-square-foot lab complements the company’s Branford laboratory, which was expanded in early 2020 to meet greater demand, including COVID-19 testing. Sema4 has more than 500 full-time employees in Connecticut—a number that has quadrupled over the last three years—and recently closed financing at a post-money valuation of more than $1 billion.